

2018-2019

American Heart Association

Support from Pharmaceutical and Biotech Companies, Device Manufacturers and Health Insurance Providers

We value the trust placed in us by our donors, supporters and the general public, and we feel the best way to continue to earn that trust is to make the association's finances as transparent as possible. In fact, the American Heart Association has consistently met the high standards of the [Better Business Bureau's Wise Giving Alliance \(WGA\)](#), the premier organization evaluating charitable organizations.


Most of the revenue recorded by the American Heart Association comes from sources other than corporations. These sources include contributions from individuals, foundations and estates as well as investment earnings and revenue from the sale of educational materials.

Financial support from corporations helps the association's programs and campaigns more effectively achieve our goals of improving the cardiovascular health of all Americans and saving more lives. All corporate relationships are required to comply with the association's corporate relations policies, and regional and national corporate relationships are approved by a committee of national volunteers and executive staff.

Total corporate support is comprised of unrestricted gifts and special event and program sponsorships, and includes support committed to the American Heart Association at the national, regional and local levels. Corporate Support represents approximately 19.9 percent of the AHA's \$887 million total revenue.

Support that the American Heart Association receives from pharmaceutical and biotech companies, device manufacturers and health insurance providers is included within total corporate support and represents approximately 2.3 percent of the association's total revenue. The majority of funding from these sources occurs at the national level.

The revenue figures below include the total amount of funds committed to the American Heart Association during fiscal year 2018-2019, noting that, in some cases, the funds will be received in future years. The chart provides funds committed from pharmaceutical and biotech companies, device manufacturers and health insurance providers in proportion to all sources of revenue.



Following is a schedule of corporate support provided to the American Heart Association from pharmaceutical and biotech companies, medical device manufacturers and health insurance providers during fiscal year 2018-2019. The schedule reflects cash received during fiscal year 2018-2019 and revenue committed to the American Heart Association that will be received in future years.

2018-2019 Corporate Support Received from Pharmaceutical and Biotech Companies, Medical Device Manufacturers and Health Insurance Providers		
Corporation	Total Cash Received During 2018-2019 on Prior and Current Year Commitments (1)	2018-2019 Commitments Receivable in the Future
3M	100,000	-
Abbott	2,500	-
Amarin	295,000	740,000
AmerisourceBergen	-	200,000
Amgen	1,324,667	705,000
Anthem	1,467,044	-
Arbor Pharmaceuticals	5,000	-
Assurance	125,000	-
AstraZeneca	7,248,365	1,280,000
Bard/BD	5,000	-
Bayer Healthcare	968,246	45,000
Biogen	10,500	-
Blue Cross Blue Shield of NC	-	750,000
Blue Shield of California	250,000	-
BMS/Pfizer	817,500	-
BI/Lilly	3,000,000	-
Biosense Webster	15,000	-
Boehringer Ingelheim Pharmaceuticals	500,000	1,527,450
Chiesi	15,000	-
Denka Seiken USA	-	20,000
Edwards Lifesciences LLC	400,000	-
Esperion Therapeutics, Inc.	-	12,500
Florida Blue	150,000	150,000
Gore Medical	-	30,000
Humana	-	375,000
Ionis	1,500	-
Independence Blue Cross	125,000	-
Jabil	75,000	-
Janssen	433,335	-
Janssen Biotech	-	143,335
Johnson & Johnson	625,353	-
Kaiser Permanente	525,000	675,000
Laerdal Medical Corporation	610,000	-
Medtronic/Covidien/EV3	1,472,500	260,000
Merck	60,000	-
MyoKardia	25,000	-
Nephron Pharmaceuticals	75,000	-
Novartis Pharmaceuticals	3,431,456	1,172,170
NovoNordisk	2,036,378	60,000
Parker Hannifin	-	125,000
Pfizer	824,595	35,000
Philips Healthcare	200,000	125,000
Physio-Control	14,250	-
Portola Pharmaceuticals, Inc.	88,500	30,000
Quest Diagnostics	1,000,000	-
Reckitt Benckiser	-	375,000
Regeneron	125,000	-
Relypsa	7,500	-
Sanofi	117,500	3,125,000
Schiller Americas, Inc.	-	450,000
Siemens USA	-	200,000
Stryker Neurovascular	-	14,250
The Medicines Company	-	320,000
Transamerica	1,035,000	500,000
UnitedHealthcare	-	150,000
Verily (Google Life Science)	3,052,934	-
Verve Therapeutics	-	5,000
Western Health Advantage	115,000	-
WorldPoint	25,000	-
Zoll Medical	28,500	-
Totals	32,828,123	13,599,705

NOTE: (1) Reflects all cash received from corporate contributions to National Center and ten highest corporate contributions to each Region. Revenue related to the cash receipts was recorded within AHA's financial statements over the periods from fiscal year 2014-15 through fiscal year 2018-19.